{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:28:08Z","timestamp":1766579288439,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"F. Hoffmann-La Roche Ltd This is not for the individual author, but the manuscript overall"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A clearer understanding of the prognostic implications of t(11;14) in multiple myeloma (MM) is needed to inform current and future therapeutic options. We utilized real-world data from a US database to examine treatment patterns and outcomes in patients by t(11;14) status compared with high- and standard-risk subgroups across different lines of therapy (LoT). This retrospective, observational cohort study used de-identified patient-level information from adults with MM and first-line treatment initiation between January 2011 and January 2020, followed until February 2020. The high-risk cohort comprised patients with high-risk genetic abnormalities per mSMART criteria (including those with co-occurring t(11;14)). Among 6138 eligible patients, 6137, 3160, and 1654 received first-, second-, and third-line treatments, respectively. Of 645 patients who had t(11;14), 69.1% had t(11;14) alone, while 30.9% had co-occurring high-risk abnormalities. Altogether, 1624 and 2544 patients were classified as high- and standard-risk, respectively. In the absence of biomarker-driven therapy, treatment patterns remain similar across LoT in high-risk, t(11;14)+, and standard-risk subgroups. Across all LoT, patient outcomes in the high-risk subgroup were less favorable than those in the t(11;14)+ and standard-risk subgroups. Thus, there is an opportunity for novel therapeutics targeted to t(11;14) and other defined subgroups to personalize MM therapy and optimize patient outcomes.<\/jats:p>","DOI":"10.1038\/s41408-022-00638-0","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T08:02:35Z","timestamp":1648022555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis"],"prefix":"10.1038","volume":"12","author":[{"given":"Shebli","family":"Atrash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn M.","family":"Flahavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esprit","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeep","family":"Karve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Jen","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Jirau-Lucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"638_CR1","unstructured":"Cancer Network. Multiple myeloma: statistics. 2021. https:\/\/www.cancer.net\/cancer-types\/multiple-myeloma\/statistics."},{"key":"638_CR2","unstructured":"National Cancer Institute. Cancer stat facts: myeloma. 2021. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"638_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"638_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/10428194.2020.1827253","volume":"62","author":"M Braunlin","year":"2021","unstructured":"Braunlin M, Belani R, Buchanan J, Wheeling T, Kim C. Trends in the multiple myeloma treatment landscape and survival: a US analysis using 2011\u20132019 oncology clinic electronic health record data. Leuk Lymphoma. 2021;62:377\u201386.","journal-title":"Leuk Lymphoma"},{"key":"638_CR5","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/blood.V92.3.802","volume":"92","author":"J Drach","year":"1998","unstructured":"Drach J, Ackermann J, Fritz E, Kr\u00f6mer E, Schuster R, Gisslinger H, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802\u20139.","journal-title":"Blood."},{"key":"638_CR6","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1182\/blood.V95.6.1925","volume":"95","author":"N Zojer","year":"2000","unstructured":"Zojer N, K\u00f6nigsberg R, Ackermann J, Fritz E, Dallinger S, Kr\u00f6mer E, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95:1925\u201330.","journal-title":"Blood."},{"key":"638_CR7","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","volume":"101","author":"R Fonseca","year":"2003","unstructured":"Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569\u201375.","journal-title":"Blood."},{"key":"638_CR8","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119:2100\u20135.","journal-title":"Blood."},{"key":"638_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/ccr3.76","volume":"2","author":"C Jo\u00e3o","year":"2014","unstructured":"Jo\u00e3o C, Costa C, Coelho I, Vergueiro MJ, Ferreira M, da Silva MG. Long-term survival in multiple myeloma. Clin Case Rep. 2014;2:173\u20139.","journal-title":"Clin Case Rep."},{"key":"638_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1200\/EDBK_175171","volume":"37","author":"A Rosko","year":"2017","unstructured":"Rosko A, Giralt S, Mateos MV, Dispenzieri A. Myeloma in elderly patients: when less is more and more is more. Am Soc Clin Oncol Educ Book. 2017;37:575\u201385.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"638_CR11","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1182\/bloodadvances.2019001425","volume":"4","author":"S Giri","year":"2020","unstructured":"Giri S, Huntington SF, Wang R, Zeidan AM, Podoltsev N, Gore SD, et al. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Adv. 2020;4:2245\u201353.","journal-title":"Blood Adv"},{"key":"638_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-0284-7","volume":"10","author":"CR Marinac","year":"2020","unstructured":"Marinac CR, Ghobrial IM, Birmann BM, Soiffer J, Rebbeck TR. Dissecting racial disparities in multiple myeloma. Blood Cancer J. 2020;10:1\u20138.","journal-title":"Blood Cancer J"},{"key":"638_CR13","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.V88.2.674.bloodjournal882674","volume":"88","author":"M Chesi","year":"1996","unstructured":"Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996;88:674\u201381.","journal-title":"Blood."},{"key":"638_CR14","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","volume":"100","author":"R Fonseca","year":"2022","unstructured":"Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar VS, Hoyer JD, Lust JA, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2022;100:1417\u20132.","journal-title":"Blood."},{"key":"638_CR15","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1182\/blood.V99.6.2185","volume":"99","author":"H Avet-Loiseau","year":"2002","unstructured":"Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99:2185\u201391.","journal-title":"Blood."},{"key":"638_CR16","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","volume":"109","author":"H Avet-Loiseau","year":"2007","unstructured":"Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome. Blood. 2007;109:3489\u201395.","journal-title":"Blood."},{"key":"638_CR17","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","volume":"106","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, et al. Clinical implications of t (11; 14)(q13; q32), t (4; 14)(p16. 3; q32), and-17p13 in myeloma patients treated with high-dose therapy. Blood. 2005;106:2837\u201340.","journal-title":"Blood."},{"key":"638_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk\u2010stratification and management. Am J Hematol. 2020;95:548\u20136.","journal-title":"Am J Hematol"},{"key":"638_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/leu.2017.204","volume":"32","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Buadi FK, et al. Natural history of t (11; 14) multiple myeloma. Leukemia. 2018;32:131\u20138.","journal-title":"Leukemia."},{"key":"638_CR20","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/ejh.13325","volume":"103","author":"C Gran","year":"2019","unstructured":"Gran C, Uttervall K, Buchfeld JB, Wallblom A, Alici E, Gahrton G, et al. Translocation (11; 14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration? Eur J Haematol. 2019;103:588\u201396.","journal-title":"Eur J Haematol"},{"key":"638_CR21","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1111\/bjh.17627","volume":"195","author":"S Bal","year":"2021","unstructured":"Bal S, Giri S, Godby KN, Costa LJ. Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma. Br J Haematol. 2021;195:e113\u20136.","journal-title":"Br J Haematol"},{"key":"638_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2015.184","volume":"30","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016;30:761\u20134.","journal-title":"Leukemia"},{"key":"638_CR23","doi-asserted-by":"crossref","unstructured":"Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, et al. Phase I\/II study evaluating the safety and efficacy of venetoclax in combination with dexamethasone as targeted therapy for patients with t(11;14) relapsed\/refractory multiple myeloma. Blood. 2019;134:926.","DOI":"10.1182\/blood-2019-125871"},{"key":"638_CR24","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1630\u201342.","journal-title":"Lancet Oncol."},{"key":"638_CR25","unstructured":"Birnbaum B, Nussbaum N, Seidl-Rathkopf K, Agrawal M, Estevez M, Estola E, et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. ArXiv:2020:2001.09765 [Preprint]. 2020. Available from: https:\/\/arxiv.org\/abs\/2001.09765."},{"key":"638_CR26","doi-asserted-by":"publisher","unstructured":"Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv:2020.03.16.20037143 2020 [Preprint]. 2020. Available from: https:\/\/doi.org\/10.1101\/2020.03.16.20037143.","DOI":"10.1101\/2020.03.16.20037143"},{"key":"638_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Baudi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88:360\u201376.","journal-title":"Mayo Clin Proc"},{"key":"638_CR28","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick BG, Gupta VA, Vertino PM, Boise LH. Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front Immunol. 2019;10:1121.","journal-title":"Front Immunol"},{"key":"638_CR29","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","volume":"99","author":"R Fonseca","year":"2002","unstructured":"Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735\u201341.","journal-title":"Blood"},{"key":"638_CR30","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","volume":"13","author":"AS Bruno","year":"2020","unstructured":"Bruno AS, Willson JL, Opalinksa JM, Nelson JJ, Lunacsek OE, Stafkey-Mailey DR, et al. Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma. Expert Rev Hematol. 2020;13:1017\u201325.","journal-title":"Expert Rev Hematol"},{"key":"638_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-017-1001-7","volume":"34","author":"Y Chen","year":"2017","unstructured":"Chen Y, Lairson DR, Chan W, Du XL. Improved survival in medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort. Med Oncol. 2017;34:1\u201312.","journal-title":"Med Oncol"},{"key":"638_CR32","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s12325-020-01546-0","volume":"38","author":"J He","year":"2021","unstructured":"He J, Schmerold L, Van Rampelbergh R, Qiu L, Potluri R, Dasgupta A, et al. Treatment pattern and outcomes in newly diagnosed multiple myeloma patients who did not receive autologous stem cell transplantation: a real-world observational study. Adv Ther. 2021;38:640\u201359.","journal-title":"Adv Ther"},{"key":"638_CR33","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","volume":"3","author":"S Ailawadhi","year":"2019","unstructured":"Ailawadhi S, Parikh K, Abouzaid S, Zhou Z, Tang W, Clancy Z, et al. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. Blood Adv. 2019;3:2986\u201394.","journal-title":"Blood Adv"},{"key":"638_CR34","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1200\/JOP.2016.020743","volume":"13","author":"American Society of Clinical Oncology.","year":"2017","unstructured":"American Society of Clinical Oncology. The state of cancer care in America, 2017: a report by the American Society of Clinical Oncology. J Oncol Pr. 2017;13:e353\u201394.","journal-title":"J Oncol Pr"},{"key":"638_CR35","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1007\/s00277-018-3446-y","volume":"97","author":"R Abonour","year":"2018","unstructured":"Abonour R, Wagner L, Durie BGM, Jagannath S, Narang M, Terebelo HR, et al. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect\u00ae MM Registry. Ann Hematol. 2018;97:2425\u201336.","journal-title":"Ann Hematol"},{"key":"638_CR36","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1002\/cam4.4137","volume":"10","author":"S Kumar","year":"2021","unstructured":"Kumar S, Williamson M, Ogbu U, Surinach A, Arndorfer S, Hong WJ. Front-line treatment patterns in multiple myeloma: an analysis of U.S.-based electronic health records from 2011 to 2019. Cancer Med. 2021;10:5866\u201377.","journal-title":"Cancer Med."},{"key":"638_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1182\/blood-2020-137100","volume":"136","author":"A Gershon","year":"2020","unstructured":"Gershon A, Liu Y, James S, Williamson M, Hong WJ, Sarsour K. Real world data (RWD) treatment patterns and sequencing of patients with multiple myeloma (MM). Blood. 2020;136:46.","journal-title":"Blood."},{"key":"638_CR38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/jnci\/djr160","volume":"103","author":"AM Ruschak","year":"2011","unstructured":"Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst. 2011;103:1007\u201317.","journal-title":"J Natl Cancer Inst"},{"key":"638_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-019-0173-0","volume":"9","author":"YX Zhu","year":"2019","unstructured":"Zhu YX, Shi CX, Bruins LA, Wang X, Riggs DL, Porter B, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019;9:1\u201312.","journal-title":"Blood Cancer J."},{"key":"638_CR40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.clml.2015.07.641","volume":"15","author":"SM Kazmi","year":"2015","unstructured":"Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Partow K, et al. Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation. Clin Lymphoma Myeloma Leuk. 2015;15:687\u201393.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"638_CR41","doi-asserted-by":"publisher","first-page":"538126","DOI":"10.3389\/fonc.2020.538126","volume":"10","author":"W Gao","year":"2020","unstructured":"Gao W, Du J, Liu J, Zhou H, Zhang Z, Jian Y, et al. What multiple myeloma with t (11; 14) should be classified into in novel agent era: standard or intermediate risk? Front Oncol. 2020;10:538126.","journal-title":"Front Oncol"},{"key":"638_CR42","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s41375-018-0098-9","volume":"32","author":"H Avet-Loiseau","year":"2018","unstructured":"Avet-Loiseau H, Facon T. Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. Leukemia. 2018;32:1267\u201376.","journal-title":"Leukemia."},{"key":"638_CR43","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, Miguel JS, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52\u201361.","journal-title":"Ann Oncol"},{"key":"638_CR44","unstructured":"National Comprehensive Cancer Network. Multiple myeloma (version 4.2022). 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma V.4.2022. \u00a9 National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed [February 3, 2022]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"638_CR45","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl J Med. 2021;384:705\u201316.","journal-title":"N. Engl J Med"},{"key":"638_CR46","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396:1563\u201373.","journal-title":"Lancet."},{"key":"638_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321.","journal-title":"Lancet Oncol"},{"key":"638_CR48","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1200\/JCO.2020.38.15_suppl.8509","volume":"38","author":"S Kumar","year":"2020","unstructured":"Kumar S, Harrison SJ, Cavo M, de La Rubia J, Popat R, Gasparetto C, et al. Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma. J Clin Oncol. 2020;38:8509.","journal-title":"J Clin Oncol"},{"key":"638_CR49","doi-asserted-by":"publisher","first-page":"TPS8554","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8554","volume":"38","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Moreau M, Dimopoulos MA, Hong WJ, Cooper S, Yu Y, et al. A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed\/refractory multiple myeloma. J Clin Oncol. 2020;38:TPS8554.","journal-title":"J Clin Oncol"},{"key":"638_CR50","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","volume":"39","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ, et al. Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol. 2021;39:3602\u201312.","journal-title":"J Clin Oncol"},{"key":"638_CR51","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017;130:2401\u20139.","journal-title":"Blood."},{"key":"638_CR52","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajh.26083","volume":"96","author":"JL Kaufman","year":"2021","unstructured":"Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, et al. Targeting BCL\u20102 with venetoclax and dexamethasone in patients with relapsed\/refractory t (11;14) multiple myeloma. Am J Hematol. 2021;96:418\u201327.","journal-title":"Am J Hematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00638-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T20:06:07Z","timestamp":1669233967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00638-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["638"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00638-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"type":"electronic","value":"2044-5385"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"assertion":[{"value":"27 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SA: employment (Levine Cancer Institute, Atrium Health), research funding (Amgen, GSK, Karyopharm), honoraria (Takeda, Amgen, Karyopharm, BMS, Sanofi, Cellectar, Janssen, Celgene), speaker\u2019s bureau (BMS, Janssen Oncology, Sanofi); EMF: employment (Roche Products Limited), equity (F. Hoffmann-La Roche Ltd); TX: employment and equity (F. Hoffmann-La Roche Ltd), previous employment (Roche Diagnostics GmbH); EM: employment and equity (Genentech, Inc.); SK: employment and equity (AbbVie); W-JH: previous employment (Genentech, Inc.\/F. Hoffmann-La Roche Ltd), equity (F. Hoffmann-La Roche Ltd), new affiliation (Imago BioSciences, Inc.); GJ-L: employment (Genentech, Inc.), equity (BMS, AbbVie), divested equity (Celgene); MN: employment and equity (Genentech, Inc.\/F. Hoffmann-La Roche Ltd); SA: research funding to the institution (Pharmacyclics, Cellectar, Amgen, Janssen, BMS, Medimmune, Phosplatin), honoraria (Takeda, Celgene).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}